Armata Pharmaceuticals Receives Additional $3.7M In Non-dilutive Funds From US Department Of War For Phase 3 Development Program For AP-SA02

Importantly, the $3.7 million represents the first funding received specifically for Phase 3 execution pursuant to a previously announced DoW award, received through the Medical Technology Enterprise Consortium ("MTEC") and managed by the Naval Medical Research Command ("NMRC") – Naval Advanced Medical Development ("NAMD") with funding from the Defense Health Agency and Joint Warfighter Medical Research Program. This funding follows the $28.7 million previously provided, bringing cumulative non-dilutive DoW funding under the award to approximately $32.4 million and underscoring the U.S. government's continued interest in advancing the AP-SA02 program.Armata's lead clinical candidate, AP-SA02, is being developed as an adjunctive treatment for complicated Staphylococcus aureus bacteremia ("SAB") caused by methicillin-sensitive S. aureus ("MSSA") or methicillin-resistant S. aureus ("MRSA"). The additional funding will be used to support the Phase 3 clinical program for AP-SA02."The DoW has supported the AP-SA02 program through multiple stages of its development, and these new funds extend that support into Phase 3," said Dr. Deborah Birx, Chief Executive Officer of Armata."We believe the continued commitment of non-dilutive federal funding reflects the importance of developing new approaches to serious and difficult-to-treat bacterial infections, including antibiotic-resistant S. aureus. Complicated SAB remains associated with substantial morbidity and mortality in both military and civilian populations, underscoring the need for therapies that can complement existing antibiotics and improve outcomes for patients."Dr. Birx continued, "We view this funding as the first commitment of DoW support for the Phase 3 program, and we intend to continue working closely with the DoW regarding potential additional support as the Phase 3 study advances. Our long-standing collaboration has helped us move the program from early clinical development toward a pivotal study, while providing meaningful non-dilutive capital to support its advancement."About AP-SA02Armata is developing AP-SA02, a fixed multi-phage cocktail, for the adjunct treatment of complicated SAB caused by MSSA or MRSA. AP-SA02 has received Qualified Infectious Disease Product (QIDP) designation, Fast Track designation, and Breakthrough Therapy designation from the FDA. The diSArm study (NCT05184764) was a Phase 1b/2a, multicenter, randomized, double-blind, placebo-controlled, multiple ascending dose escalation study of the safety, tolerability, and efficacy of intravenous AP-SA02 in addition to best available antibiotic therapy ("BAT") compared to BAT alone (placebo) for the treatment of adults with complicated SAB. Positive results from the Phase 2a diSArm study were highlighted in a late-breaking oral presentation at IDWeek 2025™ in October 2025. The Company plans to advance AP-SA02 into a Phase 3 superiority study in complicated SAB, anticipated to initiate in the second half of 2026.